Literature DB >> 8104333

The impact of lag time on the estimation of pharmacokinetic parameters. I. One-compartment open model.

N G Nerella1, L H Block, P K Noonan.   

Abstract

Lag time in pharmacokinetics corresponds to the finite time taken for a drug to appear in systemic circulation following extravascular administration. Lag time is a reflection of the processes associated with the absorption phase such as drug dissolution and/or release from the delivery system and drug migration to the absorbing surface. Failure to specify the lag time can lead to inappropriate or erroneous estimates of pharmacokinetic parameters. This has been demonstrated in the case of a one-compartment open model by the pharmacokinetic analysis of bioequivalence data from a study involving the administration of propoxyphene napsylate to human volunteers. Subsequently, pharmacokinetic and statistical analyses of data obtained from a series of 49 simulations involving a wide range of absorption and elimination rate constants (0.05 to 5.00 and 0.01 to 0.95 hr-1, respectively) showed that lag time has a substantial effect on several primary and secondary pharmacokinetic parameters.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104333     DOI: 10.1023/a:1018970924508

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

1.  Unique pharmacokinetic characteristics of the one-compartment first-order absorption model with equal absorption and elimination rate constants.

Authors:  J G Zhi
Journal:  J Pharm Sci       Date:  1990-07       Impact factor: 3.534

2.  Pharmacokinetic model equations for the one- and two-compartment models with first-order processes in which the absorption and exponential elimination or distribution rate constants are equal.

Authors:  H P Wijnand
Journal:  J Pharmacokinet Biopharm       Date:  1988-02

3.  Concentration ratio method to determine the rate constant for the special case when ka = ke.

Authors:  I H Patel
Journal:  J Pharm Sci       Date:  1984-06       Impact factor: 3.534

4.  Graphical approach for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes.

Authors:  P E Macheras
Journal:  J Pharm Sci       Date:  1985-05       Impact factor: 3.534

5.  Nonlinear regression approach for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes.

Authors:  K K Chan; K W Miller
Journal:  J Pharm Sci       Date:  1983-05       Impact factor: 3.534

6.  Developments in the concentration ratio method.

Authors:  P E Macheras
Journal:  J Pharm Sci       Date:  1985-09       Impact factor: 3.534

7.  A simple method for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes.

Authors:  M Bialer
Journal:  J Pharmacokinet Biopharm       Date:  1980-02
  7 in total
  11 in total

1.  Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.

Authors:  A Ring; L Tothfalusi; L Endrenyi; M Weiss
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

2.  The effect of operational stressors on ibuprofen pharmacokinetics.

Authors:  Cathy Boscarino; Andrea N Edginton; Henry Peng; K Wayne Riggs; András Szeitz; Bob Cheung
Journal:  Eur J Clin Pharmacol       Date:  2012-05-31       Impact factor: 2.953

3.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

4.  Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.

Authors:  Fredrik Sjöö; Ibrahim El-Serafi; Jon Enestig; Jonas Mattsson; Johan Liwing; Moustapha Hassan
Journal:  Clin Drug Investig       Date:  2014-01       Impact factor: 2.859

Review 5.  Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.

Authors:  Rong Wang; Dale P Conner; Bing V Li
Journal:  AAPS J       Date:  2016-12-21       Impact factor: 4.009

6.  Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

Authors:  Stefan S De Buck; Annamaria Jakab; Markus Boehm; Douglas Bootle; Dejan Juric; Cornelia Quadt; Timothy K Goggin
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

7.  Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.

Authors:  Oleg Demin; Tatiana Yakovleva; Dmitry Kolobkov; Oleg Demin
Journal:  Front Pharmacol       Date:  2014-10-13       Impact factor: 5.810

8.  A population pharmacokinetic approach to describe cephalexin disposition in adult and aged dogs.

Authors:  Ana Paula Prados; Paula Schaiquevich; Verónica Kreil; Agustina Monfrinotti; Pamela Quaine; Lisa Tarragona; Ruben Hallu; Marcela Rebuelto
Journal:  Vet Med Int       Date:  2014-11-06

9.  Safety Evaluation of Parastar® Plus in Dogs and Assessment of Transferable Residue of Fipronil and Cyphenothrin from Dogs to Humans.

Authors:  Katharine M Case; Natalia M Vega; Ramesh C Gupta; Michelle A Lasher; Terry D Canerdy
Journal:  Front Vet Sci       Date:  2016-09-30

Review 10.  Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.

Authors:  Grace Chen; Astrid-Maria Højer; Johan Areberg; George Nomikos
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.